CN113474346B - 用于抑制泛素特异性蛋白酶1的组合物 - Google Patents

用于抑制泛素特异性蛋白酶1的组合物 Download PDF

Info

Publication number
CN113474346B
CN113474346B CN201980093028.5A CN201980093028A CN113474346B CN 113474346 B CN113474346 B CN 113474346B CN 201980093028 A CN201980093028 A CN 201980093028A CN 113474346 B CN113474346 B CN 113474346B
Authority
CN
China
Prior art keywords
alkyl
compound
cycloalkyl
nitrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980093028.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN113474346A (zh
Inventor
A·J·巴克麦尔特
J·A·卡拉维尔拉
J·林
E·L·弗里岑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forma Therapeutics Inc
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of CN113474346A publication Critical patent/CN113474346A/zh
Application granted granted Critical
Publication of CN113474346B publication Critical patent/CN113474346B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980093028.5A 2018-12-28 2019-12-27 用于抑制泛素特异性蛋白酶1的组合物 Active CN113474346B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785733P 2018-12-28 2018-12-28
US62/785,733 2018-12-28
PCT/US2019/068648 WO2020139988A1 (en) 2018-12-28 2019-12-27 Compositions for inhibiting ubiquitin specific protease 1

Publications (2)

Publication Number Publication Date
CN113474346A CN113474346A (zh) 2021-10-01
CN113474346B true CN113474346B (zh) 2024-12-27

Family

ID=71126375

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980093028.5A Active CN113474346B (zh) 2018-12-28 2019-12-27 用于抑制泛素特异性蛋白酶1的组合物

Country Status (5)

Country Link
US (1) US20220073525A1 (https=)
EP (1) EP3902802A4 (https=)
JP (1) JP7553450B2 (https=)
CN (1) CN113474346B (https=)
WO (1) WO2020139988A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10189841B2 (en) 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
US20240182481A1 (en) * 2021-02-15 2024-06-06 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
MX2023011709A (es) * 2021-04-07 2023-10-12 Forma Therapeutics Inc Inhibidor de la proteasa 1 especifica de ubiquitina (usp1).
EP4321515A4 (en) * 2021-04-09 2025-06-25 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. UBIQUITIN-SPECIFIC PROTEASE-1 INHIBITOR
KR102910851B1 (ko) * 2021-04-21 2026-01-09 장춘 진사이언스 파마슈티컬 씨오., 엘티디. 이미다졸 함유 축합고리계 유도체, 이의 제조방법 및 이의 의약적 용도
WO2022253188A1 (en) * 2021-05-31 2022-12-08 Impact Therapeutics (Shanghai) , Inc Nitrogen-containing fused heteroaromatic bicyclic compounds as usp1 inhibitors and the use thereof
JP2024540921A (ja) * 2021-10-19 2024-11-06 上海瑛派▲薬▼▲業▼有限公司 Ｕｓｐ１阻害剤としての置換トリアゾロヘテロアリール化合物及びその応用
CR20240191A (es) 2021-11-12 2024-09-13 Insilico Medicine Ip Ltd Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
US20250163049A1 (en) * 2022-02-03 2025-05-22 Exelixis, Inc. Fused bicyclic heterocyclyl compounds as usp1 inhibitors
AU2023261809A1 (en) * 2022-04-29 2024-12-05 Asieris Pharmaceuticals (Shanghai) Co., Ltd. Pyrimidine compound, method for preparing same, and pharmaceutical use thereof
WO2024006879A1 (en) * 2022-06-29 2024-01-04 Zentaur Therapeutics Usa Inc. Usp1 inhibitors and uses thereof
WO2024022519A1 (zh) * 2022-07-28 2024-02-01 先声再明医药有限公司 杂环并嘧啶类化合物及其应用
CN119790043A (zh) * 2022-08-26 2025-04-08 海南先声再明医药股份有限公司 三环类化合物及其应用
WO2024078436A1 (zh) * 2022-10-09 2024-04-18 海南先声再明医药股份有限公司 杂环并嘧啶类化合物、药物组合物及其应用
WO2024086790A1 (en) 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS
CN120603835A (zh) * 2023-01-20 2025-09-05 杭州英创医药科技有限公司 作为usp1抑制剂的化合物
WO2024233665A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
WO2024233605A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
WO2024236528A1 (en) * 2023-05-18 2024-11-21 Insilico Medicine Ip Limited Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
CN119930633B (zh) * 2023-11-06 2025-11-18 中国医学科学院药物研究所 一种吡咯并蝶啶酮类泛素特异性蛋白酶1抑制剂及其制备方法、用途和药物组合物
CN119930632B (zh) * 2023-11-06 2025-11-18 中国医学科学院药物研究所 一种三并环类泛素特异性蛋白酶1抑制剂及其制备方法、用途和药物组合物
WO2025102016A1 (en) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
WO2025151705A1 (en) 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4035893A (en) * 1991-12-17 1993-07-19 Upjohn Company, The 3-substituted imidazo (1,5-a) and imidazo (1,5-a)-triazolo (1,5-c) quinoxalines and quinazolines with cns activity
EP2170350B1 (en) * 2007-06-21 2013-09-11 Cara Therapeutics, Inc. Substituted imidazoheterocycles
EP2334672B1 (en) * 2008-09-16 2013-11-20 Proximagen Limited 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine compounds as inhibitors of SSAO
CN101824036A (zh) * 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
US10189841B2 (en) * 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RN号1060495-64-8、1069505-71-0、1069757-20-5、1070273-89-0和1070309-40-8.《STNEXT-REGISTRY》.2008, *

Also Published As

Publication number Publication date
JP2022516469A (ja) 2022-02-28
EP3902802A1 (en) 2021-11-03
CN113474346A (zh) 2021-10-01
EP3902802A4 (en) 2022-09-07
US20220073525A1 (en) 2022-03-10
WO2020139988A1 (en) 2020-07-02
JP7553450B2 (ja) 2024-09-18

Similar Documents

Publication Publication Date Title
CN113474346B (zh) 用于抑制泛素特异性蛋白酶1的组合物
CA2947338C (en) Multi-fluoro-substituted compound as bruton's tyrosine kinase (btk) inhibitor
CN110049983B (zh) 药物化合物
KR102073797B1 (ko) 단백질 키나제 저해제로서의 아미노피리다지논 화합물
JP6196615B2 (ja) 化合物、その医薬組成物、及び癌治療用の阻害薬としてのその使用
KR102219160B1 (ko) N-(4-(아자인다졸-6-일)-페닐)-설폰아미드 및 약제로서의 그의 용도
JP6267231B2 (ja) カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
CN113365989A (zh) Ezh2抑制剂及其用途
CN112538072A (zh) 新型氨基嘧啶类egfr抑制剂
EP3458460B1 (en) Imidazoles as histone demethylase inhibitors
EP3917527A1 (en) Compounds and uses thereof
JP2017510564A (ja) 新規なヘテロ芳香族誘導体およびそれらの医薬としての使用
WO2016170323A1 (en) Isoxazolyl substituted imidazopyridines
US12492197B2 (en) 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof
EP3668877B1 (en) Indole derivatives as histone demethylase inhibitors
RS57545B1 (sr) Novi derivati indola i pirola, postupak njihove izrade i farmaceutske kompozicije koje ih sadrže
WO2021018869A1 (en) 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer
KR20190098266A (ko) 치환된 축합 헤테로아릴기 화합물인 키나제 억제제 및 이의 응용
CN119490500A (zh) 一种prmt5抑制剂、其制备方法及应用
WO2023209088A1 (en) Bicyclic heteroaromatic compounds and their use in the treatment of cancer
KR20250151455A (ko) Egfr 억제제로서의 마크로시클릭 아미노피리딘 화합물
WO2023209090A1 (en) Bicyclic heteroaromatic compounds and their application in the treatment of cancer
CN120187426A (zh) 发动蛋白活化剂
JP2025516171A (ja) 縮合二環式ヘテロ芳香族化合物及び癌の治療におけるその使用
CN112521372A (zh) 一种细胞凋亡蛋白抑制剂及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant